Background {#Sec1}
==========

Bladder cancer, also known as urothelial cancer of the bladder, is the most common malignancy affecting the urinary system \[[@CR1]--[@CR3]\]. Treatment of bladder cancer has not advanced in the past 30 years \[[@CR1]\]. The disease has a multifactorial etiology that includes environmental factors such as cigarette smoking, arsenic exposure and occupational exposure as well as genetic factors \[[@CR4]--[@CR6]\]. Genetic factors are the one of the most important factors associated with the onset of bladder cancer \[[@CR7]\]. Smoking is a major risk factor for the development of this cancer, but the functional consequences of the carcinogens in tobacco smoke in terms of bladder cancer--associated metabolic changes remain poorly defined. Current evidence indicates that some gene polymorphisms are associated with bladder cancer morbidity \[[@CR8]--[@CR12]\].

Glutathione S-transferases (GSTs) play an important role in detoxification of various toxic compounds, such as carcinogens, and are a family of enzymes that include the glutathione S-transferase μ1 (GSTM1), θ1 (GSTT1) and π1 (GSTP1) classes, etc. \[[@CR13]\]. They are important phase II detoxifying enzymes that catalyze the conjugation of reduced glutathione (GSH) to hydrophobic, electrophilic xenobiotic substances \[[@CR14]\]. Genetic risk to malignant tumors has led to the accumulating attention to the investigations of genes polymorphism involved in process of carcinogenesis \[[@CR15]\]. The gene polymorphisms of GSTs might influence the detoxification activities of the enzymes, predisposing individuals to cancers, such as oral squamous-cell carcinoma, gynecological cancer, breast cancer, prostate cancer, hepatocellular carcinoma, and colorectal cancer \[[@CR16]--[@CR21]\].

In the past few decades, most of the epidemiological investigations have focused on the relationship between the null genotypes for GSTM1-GSTT1 and bladder cancer susceptibility. However, available evidence is inadequate due to the sparseness of data or disagreements among reported studies. We performed this meta-analysis to investigate whether the dual-null GSTM1-GSTT1 genotype was associated with bladder cancer susceptibility.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We retrieved relevant published articles from the electronic databases of PubMed, Embase, the Cochrane Library and the China Biological Medicine Database (CBM-disc) on July 1, 2017, and we recruited eligible original articles for our meta-analysis. Key search terms consisted of \["glutathione S-transferases" OR "GSTs" OR "GSTM1" OR "GSTT1"\] and \["bladder cancers" OR "bladder cancer"\]. We identified additional articles through references cited in retrieved articles, and we also examined citations of retrieved articles and the previous meta-analyses.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

### Inclusion criteria {#Sec5}

\(1\) The endpoint of each study had to be bladder cancers. (2) The study had to include 2 comparison groups (bladder cancers vs. controls). (3) The study had to provide detailed data on genotype distribution.

### Exclusion criteria {#Sec6}

\(1\) Case reports, review articles and editorials. (1) Preliminary results not focused on GSTM1, GSTT1 or outcome. (3) Investigating the relationship of GST gene expression to disease. (4) Multiple publications.

Quality appraisal {#Sec7}
-----------------

To evaluate the quality of the recruited articles that met the above-listed inclusion criteria, we used a quality score based on 7 aspects of genetic-association studies (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Thakkinstian et al. \[[@CR22]\] created the quality score form in 2005; its range spans from 0 (worst quality) to 12 (best quality). Two researchers who were responsible for literature retrieval appraised quality independent of one another, and a discussion was made until every respect was entirely consistent by comparison.

Data extraction and synthesis {#Sec8}
-----------------------------

Two investigators independently excerpted the following information from each eligible study: first author's surname, year of publication, and number of cases and controls for both the GSTM1 and GSTT1 genotypes. We calculated frequencies for both the disease group and the control group from the corresponding genotype distribution. Finally, we compared the results and resolved any disagreements by discussion. We tested the consistency of the data extracted by the 2 researchers, and any disagreement was again resolved by discussion.

Statistical analysis {#Sec9}
--------------------

We performed all statistical analyses using Cochrane Review Manager Software, version 5 (RevMan 5; Cochrane Library, UK). We used *I*^*2*^ to test heterogeneity among the included studies, and we counted the pooled statistic using a fixed-effects model (Cochran--Mantel--Haenszel method), but switched to a random-effects model (DerSimonian--Laird method) when the *P*-value of the heterogeneity test was \< 0.1. Results were expressed with odds ratios (ORs) for dichotomous data, and we also calculated 95% confidence intervals (CIs). *P* \< 0.05 was required for the pooled OR to be statistically significant. We graphically judged publication bias from the Begg adjusted-rank correlation test \[[@CR23]\] and the Egger regression asymmetry test \[[@CR24]\] using the Stata version 12.0 (Stata Corporation, College Station, TX), and *P*-values \< 0.1 were considered significant.

Results {#Sec10}
=======

Study characteristics for the GSTM1-null genotype and bladder cancer risk {#Sec11}
-------------------------------------------------------------------------

We included 72 studies \[[@CR25]--[@CR96]\], which contained 20,239 case series and 24,393 controls, in our assessment of the relationship between the GSTM1-null genotype and bladder cancer susceptibility (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). We extracted data of interest: first author's surname, year of publication and number of cases and controls for the GSTM1-null genotype (Table [1](#Tab1){ref-type="table"}). Average distribution frequency of the GSTM1-null genotype was 56.15% in the bladder cancer group and 46.97% in the control group, indicating that the GSTM1-null genotype was higher in the bladder cancer cases than in the controls (case/control = 1.20).Fig. 1Flow chart of the study search and selectionTable 1Characteristics of the studies evaluating effects of the GSTM1-null genotypes on bladder carcinogen riskAuthor, yearCountryEthnicitySource of controlsQuality ScoreCaseControl--+total--+totalBell 1993USAOverallPopulation-based91118920085115200CaucasianPopulation-based61391005050100AfricanPopulation-based50501003565100Daly 1993UKCaucasianPopulation-based445853312758Zhong 1993UKCaucasianHospital-based439589794131225Lin 1994USA, etcOverallPopulation-based66146107442473915CaucasianPopulation-based523789236243479AsianPopulation-based516179170349AfricanPopulation-based4812276087Okkels 1996DenmarkCaucasianHospital-based7133100233100100200Anwar 1996EgyptAfricanPopulation-based919322101121Brockmoller 1996GermanyCaucasianHospital-based8217157374192181373Lafuente 1996EgyptAfricanPopulation-based5392766282755Katoh 1998JapanAsianHospital-based966461125062112Abdel-Rahman 1998EgyptAfricanHospital-based8261137151934Salagovic 1999SlovakiaCaucasianHospital-based6403676123125248Mungan 2000NetherlandsCaucasianHospital-based4382361303969Peluso 2000ItalyCaucasianHospital-based56169130292554Schnakenberg 2000GermanyCaucasianPopulation-based6936415712994223Steinhoff 2000GermanyCaucasianHospital-based780551355770127Georgiou 2000GreeceCaucasianHospital-based65633895691147Kim 2000KoreaAsianHospital-based6783411212897225Toruner 2001TurkeyAsianHospital-based875461215566121Aktas 2001TurkeyAsianPopulation-based4564710370132202Giannakopoulos 2002GreeceCaucasianHospital-based65633895691147Kim 2002KoreaAsianPopulation-based813878216265184449Lee 2002KoreaAsianHospital-based8149832328679165Ma 2002ChinaAsianPopulation-based81801373179983182Schroeder 2003USAMixHospital-based813793230101112213Jong 2003KoreaAsianPopulation-based9755112699105204Moore 2004USAMixPopulation-based854521064960109Srivastava 2004IndiaAsianHospital-based7426410654128182Hung 2004FranceCaucasianHospital-based713269201112102214Saad 2005UKCaucasianPopulation-based8452772404181Srivastava 2005IndiaAsianPopulation-based101402303704363106Sobti 2005IndiaAsianPopulation-based93763100245276Garcia-Closas 2005SpainCaucasianHospital-based971642211385715611132Karagas 2005USAMixPopulation-based9210134344309233542Kim 2005KoreaAsianHospital-based792611537380153McGrath 2006USAMixPopulation-based1110982191483439922Ouerhani 2006TunisiaAfricanPopulation-based6392362364379Murta-Nascimento 2007SpainCaucasianHospital-based8428251679367368735Moore 2007SpainCaucasianHospital-based768339410775244981022Cengiz 2007TurkeyCaucasianHospital-based6341751223153Kellen 2007BelgiumCaucasianPopulation-based83122675795974661063Zhao 2007USACaucasianHospital-based8324298622317316633Shao 2008ChinaAsianHospital-based108511720281191272Yuan 2008USAMixPopulation-based11387275662335351686Covolo 2008ItalyCaucasianHospital-based712869197111100211Golka 2008GermanyCaucasianHospital-based71841092938888176Song 2009ChinaAsianHospital-based1113177208108104212Altayli 2009TurkeyCaucasianHospital-based758771356563128Grando 2009BrazilMixPopulation-based740601003367100Lin 2009USAMixPopulation-based9312292604286324610Zupa 2009ItalyCaucasianPopulation-based81310236853121Abd 2010EgyptAfricanHospital-based61192091120Moore 2011USAMixHospital-based1065340010536905451235Öztürk 2011TurkeyCaucasianPopulation-based89878176514697Rouissi 2011TunisiaAfricanPopulation-based763621255669125Salinas-Sonchez 2011SpainCaucasianHospital-based51099220178115193Goerlitz 2011EgyptAfricanHospital-based9344274618332289621Marenne 2012SpainCaucasianHospital-based7488285773402357759Ovsiannikov 2012GermanyCaucasianHospital-based610294196123112235Schwender 2012GermanyCaucasianHospital-based790966315728638761739Henriquez-Hernondez 2012SpainCaucasianHospital-based8236790176481Lesseur 2012New HampshireCaucasianHospital-based9378275653508420928Zhang 2012USAMixHospital-based10381329710402380782Matic 2013SerbiaCaucasianHospital-based8111902016161122Savic-Radojevic 2013SerbiaCaucasianHospital-based6453580322860Safarinejad 2013IranAsianHospital-based105011616693239332Wang 2013ChinaAsianHospital-based769935110508345701404Berber 2013TurkeyCaucasianHospital-based754601145163114Kang 2013KoreaAsianHospital-based96545110103117220Reszka 2014PolandCaucasianPopulation-based914995244165200365Ceylan 2015TurkeyCaucasianHospital-based8224365313970Elhawary 2017Saudi ArabiaAsianHospital-based72428524064104Ali 2017PakistanAsianPopulation-based118311720057143200

In the subgroup of patients and controls who smoked cigarettes, we included 24 studies \[[@CR25], [@CR30], [@CR34], [@CR35], [@CR42], [@CR43], [@CR47], [@CR48], [@CR50], [@CR51], [@CR54]--[@CR56], [@CR64], [@CR65], [@CR68], [@CR69], [@CR73], [@CR76], [@CR83], [@CR85], [@CR91], [@CR92], [@CR95]\] (data not shown) containing 3724 case series and 3160 controls. Average distribution frequency of the GSTM1-null genotype was 55.67% in the bladder cancer group and 47.57% in the control group, indicating that the GSTM1-null genotype was significantly higher in the bladder cancer cases compared with the controls (case/control = 1.17).

Study characteristics for GSTT1-null genotype and bladder cancer risk {#Sec12}
---------------------------------------------------------------------

We included 61 studies \[[@CR29], [@CR32]--[@CR34], [@CR36]--[@CR40], [@CR42]--[@CR45], [@CR47]--[@CR53], [@CR55]--[@CR61], [@CR63]--[@CR69], [@CR72]--[@CR74], [@CR76], [@CR77], [@CR79], [@CR83]--[@CR86], [@CR89], [@CR91], [@CR92], [@CR95]--[@CR108]\] containing 13,041 case series and 16,739 controls in our assessment of the relationship between the GSTT1-null genotype and bladder cancer risk (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Average distribution frequency of the GSTT1-null genotype was 29.58% in the bladder cancer group and 26.67% in the control group, indicating that the GSTT1 -null genotype was higher in the bladder cancer cases compared with the controls (case/control = 1.11).Table 2Characteristics of the studies evaluating effects of the GSTT1-null genotype of on bladder carcinogen riskAuthor, YearCountryEthnicitySource of controlsQuality scoreCaseControl--+total--+totalBrockmoller 1996GermanyCaucasianHospital-based86630837478295373Kempkes 1996GermanyCaucasianPopulation-based7209311331139170Abdel-Rahman 1998EgyptAfricanHospital-based817203752934Katoh 1998JapanCaucasianHospital-based946661125953112Kim 1998KoreaAsianHospital-based7184967293867Lee 1999KoreaAsianHospital-based793651586665131Salagovic 1999SlovakiaCaucasianHospital-based621557642206248Georgiou 2000GreeceCaucasianHospital-based65848916131147Peluso 2000ItalyCaucasianHospital-based51410812264854Kim 2000KoreaAsianHospital-based64765112101119220Steinhoff 2000GermanyCaucasianHospital-based72011513517110127Schnakenberg 2000GermanyAsianHospital-based62812915748175223Toruner 2001TurkeyAsianHospital-based8249712121100121Giannakopoulos 2002GreeceCaucasianHospital-based65848916131147Lee 2002KoreaAsianHospital-based8135972328580165Ma 2002ChinaAsianPopulation-based82932618894182Kim 2002KoreaAsianPopulation-based891125216228221449Gago-Dominguez 2003USAMixPopulation-based85014619634142176Jong 2003KoreaAsianHospital-based9685812611391204Chen 2004ChinaAsianPopulation-based8323062513081Moore 2004USAMixPopulation-based817891061297109Hung 2004FranceCaucasianHospital-based74315820133181214Srivastava 2004IndiaAsianHospital-based7287810629153182Sanyal 2004SwedenCaucasianPopulation-based86620427012110122Broberg 2005SwedenCaucasianPopulation-based97546122132154Garcia-Closas 2005SpainCaucasianHospital-based923089911292488731121Saad 2005UKCaucasianPopulation-based8264672146781Karagas 2005USAMixPopulation-based95383136301458759Golka 2005DortmundCaucasianHospital-based83010613638125163Kim 2005KoreaAsianHospital-based771821538964153Srivastava 2005IndiaAsianPopulation-based10287810679291370Shao 2005ChinaAsianPopulation-based7204201405195194389Sobti 2005IndiaAsianPopulation-based93070100116576McGrath 2006USAMixPopulation-based1135156191148776924Ouerhani 2006TunisiaAfricanPopulation-based6263662354479Kogevinas 2006SpainCaucasianHospital-based8247599177491Cengiz 2007TurkeyCaucasianHospital-based6183351114253Kellen 2007BelgiumCaucasianPopulation-based83016419461319380Zhao 2007USACaucasianHospital-based8103520623115519634Covolo 2008ItalyCaucasianHospital-based74215519733178211Yuan 2008USAMixPopulation-based11140518658124556680Song 2008ChinaAsianHospital-based771371085854112Altayli 2009TurkeyCaucasianHospital-based7311041359119128Grando 2009BrazilMixPopulation-based751491003763100Song 2009ChinaAsianHospital-based1111098208105107212Cantor 2010SpainCaucasianHospital-based9136542678160550710Moore 2011USAMixHospital-based1021079410042379421179Rouissi 2011TunisiaAfricanPopulation-based730951253887125Goerlitz 2011EgyptAfricanHospital-based9147470617156464620Salinas-Sánchez 2011SpainCaucasianHospital-based54214819025138163Lesseur 2012New HampshireCaucasianHospital-based9106556662143780923Ovsiannikov 2012GermanyCaucasianHospital-based63316319647188235Henriquez-Hernondez 2012SpainCaucasianHospital-based8603090404181Berber 2013TurkeyCaucasianHospital-based731831141698114Matic 2013SerbiaCaucasianHospital-based8561452013488122Safarinejad 2013IranAsianHospital-based103513116669263332Kang 2013KoreaAsianHospital-based9644611012892220Reszka 2014PolandCaucasianPopulation-based93021224277288365Ceylan 2015TurkeyCaucasianHospital-based819466596170Ali 2017PakistanAsianPopulation-based113416620026174200Elhawary 2017Saudi ArabiaAsianHospital-based764652896104

In the subgroup of patients and controls who smoked cigarettes, we included 21 studies \[[@CR34], [@CR42], [@CR43], [@CR47], [@CR48], [@CR50], [@CR51], [@CR55], [@CR56], [@CR64], [@CR65], [@CR68], [@CR69], [@CR73], [@CR76], [@CR83], [@CR85], [@CR91], [@CR92], [@CR95], [@CR97]\] (data not shown) containing 3170 case series and 2793 controls. Average distribution frequency of the GSTT1-null genotype was 29.29% in the bladder cancer group and 28.65% in the control group-that is, similar in both groups (case/control = 1.02).

Study characteristics for the dual-null GSTM1-GSTT1 genotype and bladder cancer risk {#Sec13}
------------------------------------------------------------------------------------

We included 18 studies \[[@CR32], [@CR37], [@CR39], [@CR43], [@CR47], [@CR48], [@CR52], [@CR55], [@CR58], [@CR60], [@CR63], [@CR65], [@CR67], [@CR79], [@CR84], [@CR85], [@CR89], [@CR96]\] containing 2426 case series and 3874 controls in our assessment of the relationship between the dual-null GSTM1-GSTT1 genotype and bladder cancer risk (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Average distribution frequency of the dual-null GSTM1-GSTT1 genotype was 16.78% in the bladder cancer group and 11.45% in the control group. Therefore, the dual-null GSTM1-GSTT1 genotype was significantly higher in the bladder cancer cases compared with the controls (case/control = 1.47).Table 3Characteristics of the studies evaluating effects of the GSTM1-GSTT1 dual-null genotype on bladder carcinogen riskAuthor, YearCountryEthnicitySource of controlsQuality scoreCaseControlnull-nullnon-null-nulltotalnull-nullnon-null-nulltotalAbdel-Rahman 1998EgyptAfricanHospital-based814233733134Steinhoff 2000GermanyCaucasianHospital-based7121231354123127Schnakenberg 2000GermanyCaucasianPopulation-based61214515731192223Ma 2002ChinaAsianPopulation-based816456154128182Lee 2002KoreaAsianHospital-based88314923237128165Srivastava 2004IndiaAsianHospital-based716901069173182Moore 2004USAMixPopulation-based89971066103109Hung 2004FranceCaucasianHospital-based72817320119195214Srivastava 2005IndiaAsianPopulation-based10178910632338370McGrath 2006USAMixPopulation-based111817319178844922Song 2009ChinaAsianHospital-based117713120850162212Salinas-Sonchez 2011SpainCaucasianHospital-based52013115168894Ovsiannikov 2012GermanyCaucasianHospital-based61717919629206235Henriquez-Hernondez 2012SpainCaucasianHospital-based817739087381Berber 2013TurkeyCaucasianHospital-based7111031147107114Safarinejad 2013IranAsianHospital-based103812816673259332Ceylan 2015TurkeyCaucasianHospital-based88576586270Elhawary 2017Saudi ArabiaAsianHospital-based701041040208208

Association of the GSTM1-null genotype with bladder cancer risk {#Sec14}
---------------------------------------------------------------

In this meta-analysis, we found that the GSTM1-null genotype was associated with bladder cancer risk in the overall population, and individually in whites, Africans and Asians (overall population: OR = 1.40, 95% CI: 1.31--1.48, *P*\<0.00001; whites: OR = 1.39, 95% CI: 1.26--1.54, *P*\<0.00001; Africans: OR = 1.54, 95% CI: 1.16--2.05, *P* = 0.003; Asians: OR = 1.45, 95% CI: 1.33--1.59, *P*\<0.00001); as well as in controls from both hospital-based and population-based studies that included both high- and low-quality studies (Fig. [2](#Fig2){ref-type="fig"} for the overall population; Table [4](#Tab4){ref-type="table"}). In the meta-analysis for all patients and controls who smoked cigarettes, we found that the GSTM1-null genotype was associated with bladder cancer risk in the overall population, Asians and controls from both hospital-based and population-based studies that included both high- and low-quality studies. However, we did not find this relationship in whites or Africans (Table [4](#Tab4){ref-type="table"}).Fig. 2Association between the GSTM1-null genotype and bladder cancer susceptibility in the overall populationTable 4Meta-analysis of the association of null genotypes of GSTM1, GSTT1 and dual-null genotype of GSTM1/GSTT1 with bladder carcinogens riskGenetic contrastsGroup and subgroupsStudies NumberQ test *P* valueModel selectedOR (95% CI)*P*GSTM1 - vs +Overall72\<0.00001Random1.40 (1.31,1.48)\<0.00001Caucasian37\<0.00001Random1.39 (1.26,1.54)\<0.00001Asian200.39Fixed1.45 (1.33,1.59)\<0.00001African90.10Random1.54 (1.16,2.05)0.003Hospital-based460.0001Random1.42 (1.32,1.52)\<0.00001Population-based260.003Random1.36 (1.21,1.53)\<0.00001High quality540.0002Random1.37 (1.28,1.45)\<0.00001Low quality180.0009Random1.58 (1.29,1.94)\<0.0001GSTM1 (smoking) - vs +Overall240.02Random1.37 (1.19,1.59)\<0.0001Caucasian100.007Random1.17 (0.85,1.59)0.33Asian70.63Fixed1.67 (1.32,2.11)\<0.0001African30.22Fixed1.44 (0.95,2.17)0.08High quality170.02Random1.35 (1.14,1.60)0.0005Low quality70.27Fixed1.48 (1.12,1.96)0.006GSTT1 - vs +Overall61\<0.00001Random1.11 (1.01,1.22)0.03Caucasian29\<0.00001Random1.16 (0.99,1.36)0.07Asian210.01Random1.05 (0.91,1.22)0.51African40.03Random1.07 (0.65,1.76)0.79Hospital-based40\<0.0001Random1.11 (0.99,1.24)0.07Population-based210.0002Random1.12 (0.94,1.35)0.20High quality52\<0.00001Random1.14 (1.03,1.26)0.01Low quality90.23Fixed0.93 (0.75,1.14)0.49GSTT1 (smoking)Overall210.67Fixed1.06 (0.93,1.20)0.38Caucasian90.84Fixed1.14 (0.91,1.43)0.24Asian70.62Fixed1.00 (0.77,1.30)0.99African20.41Fixed0.60 (0.36,1.02)0.06High quality160.52Fixed1.06 (0.93,1.22)0.37Low quality50.64Fixed1.01 (0.70,1.48)0.94Dual-null genotype of GSTM1/GSTT1Overall180.003Random1.48 (1.15,1.92)0.002Caucasian80.03Random1.30 (0.83,2.03)0.25Asian70.04Random1.62 (1.15,2.28)0.006Hospital-based130.03Random1.71 (1.28,2.28)0.0003Population-based50.06Random1.07 (0.67,1.71)0.77High quality150.11Fixed1.61 (1.36,1.91)\<0.00001Low quality30.04Random0.86 (0.40,1.85)0.70

Association of the GSTT1-null genotype with bladder cancer risk {#Sec15}
---------------------------------------------------------------

In this study, we found that the GSTT1-null genotype was associated with bladder cancer risk in the overall population, and controls from hospital-based studies that included high-quality studies; but not with bladder cancer risk in whites, Africans, Asians or controls from population-based studies that included low-quality studies (overall population: OR = 1.11, 95% CI: 1.01--1.22, *P* = 0.03; whites: OR = 1.16, 95% CI: 0.99--1.36, *P* = 0.07; Africans: OR = 1.07, 95% CI: 0.65--1.76, *P* = 0.79; Asians: OR = 1.05, 95% CI: 0.91--1.22, *P* = 0.51; Fig. [3](#Fig3){ref-type="fig"} for overall population; Table [4](#Tab4){ref-type="table"}). However, in controls from either hospital-based or population-based studies that included both high- and low-quality studies, or in the meta-analysis for all patients and controls who smoked cigarettes, we found that the GSTT1-null genotype was not associated with bladder cancer risk in the overall population, or in individual white, African or Asian populations (Table [4](#Tab4){ref-type="table"}).Fig. 3Association between the GSTT1-null genotype and bladder cancer susceptibility in the overall population

Association of dual-null GSTM1-GSTT1 genotype with bladder cancer risk {#Sec16}
----------------------------------------------------------------------

We found an association between the dual-null GSTM1-GSTT1 genotype and bladder cancer risk in the overall population, Asians and controls from hospital-based studies that included high-quality studies (overall population: OR = 1.48, 95% CI: 1.15--1.92, *P* = 0.002; Asians: OR = 1.62, 95% CI: 1.15--2.28, *P* = 0.006; Fig. [4](#Fig4){ref-type="fig"} for overall population; Table [4](#Tab4){ref-type="table"}). However, the dual-null GSTM1-GSTT1 genotype was not associated with onset of bladder cancer in whites or in controls from population-based studies that included low-quality studies (whites: OR = 1.30, 95% CI: 0.83--2.03, *P* = 0.25; Table [4](#Tab4){ref-type="table"}).Fig. 4Association between the dual-null GSTM1--GSTT1 genotype and bladder cancer risk in the overall population

Evaluation of publication bias {#Sec17}
------------------------------

We performed a publication bias test for the association of the GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes with bladder cancer risk in the overall population. There was no bias for the association of the dual-null GSTM1-GSTT1 genotype with bladder cancer risk, but there was for the GSTM1- and GSTT1-null genotypes (GSTM1-null: Begg *P* = 0.100, Egger *P* = 0.052; GSTT1-null: Begg *P* = 0.001, Egger *P* = 0.002; dual-null GSTM1--GSTT1: Begg *P* = 0.343, Egger *P* = 0.236; Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Publication bias. **a** GSTM1-null genotype. **b** GSTT1-null genotype. **c** Dual-null GSTM1--GSTT1 genotype

Discussion {#Sec18}
==========

Research on single-nucleotide polymorphisms have focused mainly on their impact on tumor suppressor genes, metabolic-enzyme genes, and DNA repair genes, etc. Understanding disease susceptibility and pathogenesis and using them to guide diagnosis and individual treatment choice constitute an important new therapeutic approach \[[@CR109]\]. In this study, we found that the average distribution frequency of the GSTM1-null genotype was significantly higher in bladder cancer cases than in controls (case/control = 1.20). In the subgroup of patients and controls who smoked cigarettes, it was also higher in the bladder cancer case group compared with the control group (case/control = 1.17). This might indicate that the GSTM1-null genotype was associated with bladder cancer risk in the overall population, including whites, Africans, Asians, and controls from both hospital-based and population-based studies that included both high- and low-quality studies. In the meta-analysis for all patients and controls who smoked cigarettes, we found that the GSTM1-null genotype was associated with bladder cancer risk in the overall population, Asians, and controls from both hospital-based and population-based studies that included both high- and low-quality studies. The sample size of our meta-analysis was larger than those of other meta-analyses \[[@CR61], [@CR110]--[@CR112]\], and therefore our results might be more robust. However, our tests for publication bias, the GSTM1 studies were found to be positive. Therefore, the positive association between the GSTM1-null genotype and bladder cancer should be reassessed in the future.

The average distribution frequency of the GSTT1-null genotype was higher in the bladder cancer case group than in the control group (case/control = 1.11). In the subgroup of patients and controls who smoked cigarettes, it was similar in both groups (case/control = 1.02). This might tell us that the GSTT1-null genotype was associated with bladder cancer risk. For confirmation, we performed a meta-analysis, which further showed the GSTT1-null genotype to be associated with bladder cancer risk in the overall population, whites and controls from hospital-based studies that included high-quality studies. In the meta-analysis for all patients and controls who smoked cigarettes, we found that the GSTT1-null genotype was not associated with bladder cancer risk in the overall population, whites, Africans, Asians or controls from both hospital-based and population-based studies that included both high- and low-quality studies. Our results indicate that the GSTT1-null genotype does not predict the risk of bladder cancer. The sample size of our meta-analysis was larger than those of other meta-analyses \[[@CR111], [@CR112]\], suggesting that our conclusion might be more robust. However, publication bias was also found for GSTT1. Therefore, further studies are required.

Average distribution frequency of the dual-null GSTM1-GSTT1 genotype in the bladder cancer group was slightly higher than in the control group (case/control = 1.47), indicating a possible association between the dual-null GSTM1-GSTT1 genotype and bladder cancer risk. Meta-analysis further revealed an association between the dual-null GSTM1-GSTT1 genotype and bladder cancer risk in the overall population, Asians and controls from hospital-based studies that included high-quality studies. No publication bias was found for this meta-analysis, and the conclusion was robust.

In a previous study, García-Closas et al. \[[@CR61]\] conducted a meta-analysis of 28 studies of GSTM1 and reported that the GSTM1-null genotype both increased the overall risk of bladder cancer and posed similar relative risks for both smokers and non-smokers. This finding suggested that GSTM1 lowers the risk of bladder cancer through mechanisms that are not specific to the detoxification of polycyclic aromatic hydrocarbons in tobacco smoke. Engel et al. \[[@CR110]\] performed a meta-analysis of GSTM1 and bladder cancer that included 17 studies and reported that the GSTM1-null status is associated with a modest increase in the risk of bladder cancer, and that there was no evidence of multiplicative interaction between the GSTM1-null genotype and once and current smoking in relation to bladder cancer. A meta-analysis by Yu et al. \[[@CR112]\] included 48 case--control studies for GSTM1*-null* and 57 studies for GSTT1, and suggested that the GSTM1- and GSTT1-null genotypes might both be related to higher bladder cancer risk. Yu et al. \[[@CR111]\] also performed a meta-analysis to investigate the association between GSTM1-GSTT1 deletion polymorphisms and bladder cancer susceptibility, including 46 studies of GSTM1-null, 54 of GSTT1 and 10 of dual-null GSTM1-GSTT1. All 3 genotypes were associated with increased bladder cancer risk. In our meta-analysis, we included 72 studies for GSTM1-null, 62 for GSTT1-null and 18 for dual-null GSTM1-GSTT1 genotypes. These results from the meta-analyses mentioned above were similar to our results. However, the sample size of our meta-analysis was larger than the previous meta-analyses, and the results from our studies might be more robust. Furthermore, we initially conducted a meta-analysis that showed no evidence of multiplicative interaction between the GSTT1-null genotype and smoking in relation to bladder cancer.

Smoking is a known risk factor for bladder cancer \[[@CR113]\], and the products of GSTs help detoxify the polycyclic aromatic hydrocarbons found in tobacco smoke \[[@CR114]\]. Our study suggests that the GSTM1-null genotype might play a role in such detoxification, but the GSTT1-null genotype does not. However, more studies should be conducted to confirm this.

GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes play an important role in detoxification of various toxic compounds, such as carcinogens. In this meta-analysis, it indicated that GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes were risk factors to susceptibility of bladder cancer, and took part in the pathogenesis of bladder cancer.

There were limitations in our meta-analysis. First, age might be a source of heterogeneity, but it was difficult to stratify the different ages in the reports prior to pooling the results, for the reason that the ages from most of the included studies were different. So, no conclusions can be drawn regarding the impact of GSTs on age of onset. Furthermore, heterogeneity and publication bias were both significant for GSTM1-null and GSTT1-null. Subgroup analyses were performed to find out any effect modifier, but the reason was not clear.

Conclusion {#Sec19}
==========

Our results supported that the GSTM1-null, GSTT1-null and dual-null GSTM1--GSTT1 genotypes might be associated with the onset of bladder cancers. However, more association investigations are required to further clarify these relationships.
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